CRL
Charles River Laboratories
Charles River Laboratories historical holders
total: 7
Oakmark Select Fund Charles River Laboratories transactions over time
- Total transactions:
- 4
- New positions:
- 1
- Added:
- 3
- Held since:
- 2025 Q2
- Held for:
- 4 quarters
- Latest activity:
- 2026 Q1
Bill Nygren has been an institutional investor in Charles River Laboratories (CRL) since 2025 Q2. According to 2026 Q1 report, Bill Nygren holds 1,398,000 shares with a market value of roughly $241.16M representing 3.19% of their equity portfolio. The fund/company first acquired CRL in 2025 Q2, initially purchasing 678,000 shares. Since the initial investment, Oakmark Select Fund has made 3 more transactions in this position.
Does Bill Nygren still hold CRL?
Yes, Bill Nygren continues to hold Charles River Laboratories (CRL). According to their 2026 Q1 report, they maintain a position of 1,398,000 shares valued at approximately $241.16M, representing 3.19% of their equity portfolio.
When did Bill Nygren first invest in CRL?
Bill Nygren first invested in Charles River Laboratories (CRL) in 2025 Q2 at the reported quarter-end price of $151.73 per share, acquiring 678,000 shares in their initial purchase.
What is Bill Nygren's average cost basis for CRL?
Based on historical transaction data, Bill Nygren's estimated cost basis for Charles River Laboratories (CRL) is approximately $164.29 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $164.29
CRL transactions history by Oakmark Select Fund
4 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
3.19%
|
1,398,000
|
$172.50
|
$241,155,000
|
+39.24% (+394,000)
|
+0.9%
|
|
2025 Q4
|
2.45%
|
1,004,000
|
$199.48
|
$200,277,920
|
+22.14% (+182,000)
|
+0.44%
|
|
2025 Q3
|
1.71%
|
822,000
|
$156.46
|
$128,610,120
|
+21.24% (+144,000)
|
+0.3%
|
|
2025 Q2
|
1.41%
|
678,000
|
$151.73
|
$102,872,940
|
new
|
+1.41%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.